Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Chemocentryx Inc (NQ: CCXI ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 51.97 (10) Ask (Size) 52.00 (55) Prev. Close 51.99 Today's Range N/A - N/A 52wk Range N/A - N/A Shares Outstanding 71,355,872 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share December 12, 2022 Via Benzinga How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market November 23, 2022 Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. Via Benzinga Performance More News Read More ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings October 17, 2022 From ChemoCentryx, Inc. Via GlobeNewswire Biotech Stocks Well-Positioned For The Fourth Quarter October 12, 2022 Via Talk Markets ChemoCentryx: Q2 Earnings Insights August 09, 2022 Via Benzinga ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting October 05, 2022 From ChemoCentryx, Inc. Via GlobeNewswire These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 September 20, 2022 Via Talk Markets Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year September 19, 2022 Via Investor's Business Daily Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin September 15, 2022 Via Investor's Business Daily INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI September 13, 2022 From Scott+Scott Attorneys at Law LLP Via Business Wire 7 Dow Stocks With Superior Fundamentals September 06, 2022 Via InvestorPlace Healthcare Sector Still Looks Good But Lacks Momentum September 06, 2022 Via Talk Markets ChemoCentryx's Return On Capital Employed Insights September 01, 2022 Via Benzinga INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI August 30, 2022 From Scott+Scott Attorneys at Law LLP Via Business Wire 10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others August 29, 2022 Via Investor's Business Daily Whither Small Caps After Fed’s Tough Talk? August 29, 2022 Via Talk Markets Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million August 23, 2022 Via Investor's Business Daily Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation? August 15, 2022 Via Talk Markets Why Jim Cramer Says This Financial Stock Is 'Terrific' August 12, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 August 10, 2022 Via Benzinga Earnings Preview: ChemoCentryx August 08, 2022 Via Benzinga Small Cap Biotechs Perk Up On Dealmaking August 06, 2022 Via Talk Markets Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review August 05, 2022 Via Investor's Business Daily Where ChemoCentryx Stands With Analysts August 05, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 August 05, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.